Abionyx Pharma (LTS:0RAG) Stock Based Compensation: €0.79 Mil (TTM As of Dec. 2025)


LTS:0RAG Abionyx Pharma LTS:0RAG
29 GF Score
Price €1.90
GF Value €0.85
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma Stock Based Compensation?

Abionyx Pharma LTS:0RAG 29 Stock Based Compensation is €0.79 Mil as of Dec. 2025. GuruFocus rates LTS:0RAG with a GF Score™ of 29/100 and a GF Value™ of €0.85 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Abionyx Pharma's Stock Based Compensation for the six months ended in Dec. 2025 was €0.40 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0.79 Mil.

Abionyx Pharma Stock Based Compensation Related Terms

Abionyx Pharma Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Abionyx Pharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abionyx Pharma Stock Based Compensation Chart

Abionyx Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 0.51 0.02 0.63 0.79

Abionyx Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.22 0.40 0.39 0.40
LTS:0RAG
29GF Score
Abionyx Pharma LTS:0RAG
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abionyx Pharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.79 Mil.

What does a Stock Based Compensation of €0.79 Mil mean?
Abionyx Pharma (LTS:0RAG) has a Stock Based Compensation of €0.79 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Abionyx Pharma and its competitors.
Is Abionyx Pharma's Stock Based Compensation too high?
Abionyx Pharma's current Stock Based Compensation is €0.79 Mil. Overall, Abionyx Pharma has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's Stock Based Compensation compare to VRTX and REGN?
Abionyx Pharma's Stock Based Compensation of €0.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Abionyx Pharma and its competitors. Abionyx Pharma's current Stock Based Compensation is €0.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (LTS:0RAG) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.85, compared to a current price of €1.90 — trading 123.3% above its estimated fair value. The current Stock Based Compensation is €0.79 Mil. Abionyx Pharma's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Abionyx Pharma (LTS:0RAG), the current Stock Based Compensation is €0.79 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abionyx Pharma (LTS:0RAG) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €1.90 is trading 123.3% above its estimated GF Value™ of €0.85. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for LTS:0RAG:

  • Stock Based Compensation: €0.79 Mil
  • GF Value™: €0.85 vs. price of €1.90 (123.3% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the LTS:0RAG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Other Exchanges ABNX:France609:Germany
Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
29GF Score

Get the complete analysis for LTS:0RAG

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.90
Price
€0.85
GF Value